drugset / Trial / NCT01900158

A Phase I/II Safety and Efficacy Study of PCI of Gemcitabine and Chemotherapy in Patients With Cholangiocarcinomas

NCT01900158

Phase 1 Completed 24 enrolled PCI Biotech AS
SequentialOpen-labelTreatment

Summary

This is a Phase I Dose Escalation Study in which the safety, tolerability and efficacy of Amphinex®--induced Photochemical Internalisation (PCI) of Gemcitabine followed by Gemcitabine/Cisplatin Chemotherapy will be assessed in patients with advanced inoperable cholangiocarcinomas.

Timeline

Start
2013-05
Primary completion
2019-02
Completion
2019-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Fimaporfin Other / unclassified
Background Cisplatin Other / unclassified 25 mg/m2
Background Gemcitabine Small molecule 1000 mg/m2

Indications